Prabhudas Lilladher's research report on Aurobindo Pharma
Our FY25/26E EPS estimates remains unchanged. Aurobindo Pharma’s (ARBP) Q1FY25 EBITDA of Rs16.2bn (down 4% QoQ) with OPM of 21.4% was marginally below our estimate. We expect margins to further scale up. Pick up in US sales hinge on timely niche approvals along with stabilization of pricing pressure in the base business.
Outlook
We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and PLI which are expected to be reflected from FY25. At CMP, the stock is trading at 19x FY26E P/E. We value company at 20x FY26E EPS and assign a TP of Rs1,525/share. Maintain ‘Accumulate’ rating.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
